This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luna-Herrera, J. Articles by Gangadharam, P. R. Search for Related Content PubMed PubMed Citation Articles by Luna-Herrera, J. Articles by Gangadharam, P. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Dec 1995, 2692-2695, Vol 39, No. 12
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Antituberculosis activity of clarithromycin

J Luna-Herrera, VM Reddy, D Daneluzzi and PR Gangadharam
Department of Medicine, University of Illinois at Chicago 60612, USA.

Antituberculosis activity of clarithromycin (CLA), a macrolide antibiotic, was investigated in vitro, in macrophages, and in C57BL/6 mice, CLA showed high in vitro MICs (4 to > 16 micrograms/ml) for several strains of Mycobacterium tuberculosis and caused slight enhancement of activity of rifampin (RIF) against H37Rv but failed to increase the activity of either RIF or isoniazid (INH) against other strains. However, inside J774A.1 macrophages, CLA showed high activity and was synergistic with RIF against some strains of tubercle bacilli susceptible or resistant to INH and RIF. In the in vivo studies with a drug-susceptible strain (H37Rv), CLA protected mice from mortality due to tuberculosis for up to 8 weeks of observation. The CFU data for lungs and spleens revealed that the antituberculosis activity of CLA is inferior to those of INH and streptomycin. However, the activity of CLA when used alone or in combination was comparable to that of thiacetazone, indicating its potential usefulness as a secondary drug for the treatment of tuberculosis.

This article has been cited by other articles:

• Luna-Herrera, J., Costa, M. C., Gonzalez, H. G., Rodrigues, A. I., Castilho, P. C. (2007). Synergistic antimycobacterial activities of sesquiterpene lactones from Laurus spp.. J Antimicrob Chemother 59: 548-552 [Abstract] [Full Text]  
• Andini, N., Nash, K. A. (2006). Intrinsic Macrolide Resistance of the Mycobacterium tuberculosis Complex Is Inducible.. Antimicrob. Agents Chemother. 50: 2560-2562 [Abstract] [Full Text]  
• Falzari, K., Zhu, Z., Pan, D., Liu, H., Hongmanee, P., Franzblau, S. G. (2005). In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49: 1447-1454 [Abstract] [Full Text]  
• Nash, K. A., Zhang, Y., Brown-Elliott, B. A., Wallace, R. J. Jr (2005). Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 55: 170-177 [Abstract] [Full Text]  
• Buriankova, K., Doucet-Populaire, F., Dorson, O., Gondran, A., Ghnassia, J.-C., Weiser, J., Pernodet, J.-L. (2004). Molecular Basis of Intrinsic Macrolide Resistance in the Mycobacterium tuberculosis Complex. Antimicrob. Agents Chemother. 48: 143-150 [Abstract] [Full Text]  
• Nash, K. A. (2003). Intrinsic Macrolide Resistance in Mycobacterium smegmatis Is Conferred by a Novel erm Gene, erm(38). Antimicrob. Agents Chemother. 47: 3053-3060 [Abstract] [Full Text]  
• Vester, B., Douthwaite, S. (2001). Macrolide Resistance Conferred by Base Substitutions in 23S rRNA. Antimicrob. Agents Chemother. 45: 1-12 [Full Text]  
• Bosne-David, S., Barros, V., Verde, S. C., Portugal, C., David, H. L. (2000). Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J Antimicrob Chemother 46: 391-395 [Abstract] [Full Text]